105 related articles for article (PubMed ID: 15382048)
1. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
Neumann F; Wagner C; Stevanovic S; Kubuschok B; Schormann C; Mischo A; Ertan K; Schmidt W; Pfreundschuh M
Int J Cancer; 2004 Nov; 112(4):661-8. PubMed ID: 15382048
[TBL] [Abstract][Full Text] [Related]
2. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
Wagner C; Neumann F; Kubuschok B; Regitz E; Mischo A; Stevanovic S; Friedrich M; Schmidt W; Rammensee HG; Pfreundschuh M
Cancer Immun; 2003 Dec; 3():18. PubMed ID: 14677925
[TBL] [Abstract][Full Text] [Related]
3. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
Neumann F; Kubuschok B; Ertan K; Schormann C; Stevanovic S; Preuss KD; Schmidt W; Pfreundschuh M
Cancer Immunol Immunother; 2011 Sep; 60(9):1333-46. PubMed ID: 21630107
[TBL] [Abstract][Full Text] [Related]
4. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes.
Neumann F; Wagner C; Kubuschok B; Stevanovic S; Rammensee HG; Pfreundschuh M
Cancer Immunol Immunother; 2004 Jul; 53(7):589-99. PubMed ID: 14745515
[TBL] [Abstract][Full Text] [Related]
5. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells.
Held G; Neumann F; Sturm C; Kaestner L; Dauth N; de Bruijn DR; Renner C; Lipp P; Pfreundschuh M
Int J Cancer; 2008 Oct; 123(8):1841-7. PubMed ID: 18688854
[TBL] [Abstract][Full Text] [Related]
6. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.
Wen W; Zhang L; Peng J; Chen J; Hao J; Li X; Qian X; Zeng P; Zhang Y; Yin Y
Cancer Sci; 2011 Aug; 102(8):1455-61. PubMed ID: 21595801
[TBL] [Abstract][Full Text] [Related]
7. Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells.
Neumann F; Wagner C; Preuss KD; Kubuschok B; Schormann C; Stevanovic S; Pfreundschuh M
Blood; 2005 Nov; 106(9):3105-13. PubMed ID: 16030183
[TBL] [Abstract][Full Text] [Related]
8. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
[TBL] [Abstract][Full Text] [Related]
9. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
10. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
13. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
[TBL] [Abstract][Full Text] [Related]
14. Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies.
Viehl CT; Frey DM; Phommaly C; Chen T; Fleming TP; Gillanders WE; Eberlein TJ; Goedegebuure PS
Breast Cancer Res Treat; 2008 May; 109(2):305-14. PubMed ID: 17653857
[TBL] [Abstract][Full Text] [Related]
15. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
[TBL] [Abstract][Full Text] [Related]
16. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
17. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
18. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
20. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
